Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin + R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma
CTR20181396Phase 3Active
- Sponsor
- Roche
- Start
- Jan 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Jan 2019; status: active.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20181396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181396.